Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Pembrolizumab bij niet-BCG-responsieve hoogrisico niet-spierinvasieve blaaskanker zonder CIS
jul 2024 | Uro-oncologie